GIM
JNCE

Granahan Investment Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Granahan Investment Management’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-168,424
Closed -$1.41M – 194
2021
Q4 		$1.41M Sell
168,424
-5,751
-3% -$47.4K 0.03% 180
2021
Q3 		$1.29M Sell
174,175
-183,642
-51% -$1.14M 0.02% 183
2021
Q2 		$2.43M Buy
357,817
+18,848
+6% +$157K 0.05% 177
2021
Q1 		$3.48M Sell
338,969
-61,044
-15% -$669K 0.07% 157
2020
Q4 		$2.8M Sell
400,013
-71,609
-15% -$557K 0.06% 163
2020
Q3 		$3.85M Sell
471,622
-44,126
-9% -$274K 0.13% 123
2020
Q2 		$3.56M Buy
515,748
+251,609
+95% +$1.36M 0.13% 122
2020
Q1 		$1.25M Buy
264,139
+141,857
+116% +$817K 0.07% 158
2019
Q4 		$1.07M Sell
122,282
-630
-0.5% -$3.4K 0.05% 157
2019
Q3 		$409K Buy
122,912
+6,832
+6% +$27.3K 0.02% 174
2019
Q2 		$575K Sell
116,080
-9,453
-8% -$50.2K 0.03% 174
2019
Q1 		$778K Sell
125,533
-5,860
-4% -$28.3K 0.04% 178
2018
Q4 		$443K Sell
131,393
-3,887
-3% -$18.2K 0.03% 179
2018
Q3 		$879K Buy
135,280
+3,688
+3% +$27.4K 0.05% 182
2018
Q2 		$1.01M Buy
131,592
+11,007
+9% +$159K 0.06% 183
2018
Q1 		$2.69M Buy
120,585
+2,525
+2% +$56K 0.19% 138
2017
Q4 		$1.5M Buy
+118,060
New +$1.74M 0.12% 155

Other funds holding JNCE

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Granahan Investment Management's JNCE Position: Q1 2022 in Review

Granahan Investment Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2022, closing a stake of 168,424 shares — an estimated $1.41M sold.

Granahan Investment Management first reported a position in JNCE in Q4 2017 and held it in 17 quarters. The position peaked at $3.85M in Q3 2020. 113 funds tracked by Wall St. Rank hold JNCE as of Q1 2022.

  • Granahan Investment Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Granahan Investment Management sold 168,424 Jounce Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $1.41M.
  • Granahan Investment Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2017 and held it in 17 quarters.
  • Granahan Investment Management's Jounce Therapeutics, Inc. Common Stock position peaked at $3.85M in Q3 2020.
  • 113 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Granahan Investment Management's 13F filing for Q1 2022, filed 16 May 2022.